版本:
中国

BRIEF-Pulmatrix licenses novel drug candidates from Respivert

June 13 Pulmatrix Inc-

* Pulmatrix licenses novel drug candidates from Respivert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc.

* Pulmatrix - through agreement, co gains access to a portfolio of novel drug candidates in a class called kinase inhibitors that co plans to develop Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐